




Patent Application
Attorney Docket No. PC10030A #5
4/6/01
C. styls

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this 29th day of December, 2000.

By 
(Signature of person mailing)
ROY F. WALDRON
(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: J. W. Coe et al. :
SER. NO.: 09/402,010 : Examiner: B. Coleman
FILING DATE: September 28, 1999 : Group Art Unit: 1624
TITLE: ARYL FUSED AZAPOLYCYCLIC :
COMPOUNDS :


Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:
INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Applicants submit herewith an Information Disclosure Statement pursuant to 37 C.F.R. §§ 1.97(c) and 1.98 with accompanying Form PTO-A820. This Statement is being filed after the mailing of a first Office Action on the merits but before the mailing date of either a final action or a notice of allowance. The submission of this Statement is accompanied by the fee of \$180.00 as required under 37 C.F.R. § 1.17(p).

The Commissioner is hereby authorized to charge any additional fees which may be required under 37 C.F.R. §§1.16 and 1.17, or to credit any overpayment, to Deposit Account No. 16-1445. Two copies of this paper are enclosed.


Respectfully submitted,

Date: 12/29/2000

Roy F. Waldron
Attorney for Applicant(s)
Reg. No. 42,208

Pfizer Inc
Patent Department, 20th Floor
235 East 42nd Street
New York, NY 10017-5755
(212) 733-5086

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this 29th day of December, 2000.

By



(Signature of person mailing)
ROY F. WALDRON

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: J. W. Coe et al. :
SER. NO.: 09/402,010 : Examiner: B. Coleman
FILING DATE: September 28, 1999 : Group Art Unit: 1624
TITLE: ARYL FUSED AZAPOLYCYCLIC :
COMPOUNDS :

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicants herewith make available to the U.S. Patent and Trademark Office this Information Disclosure Statement pursuant to 37 C.F.R. §§ 1.97 and 1.98, a Form PTO-FB-A820 (2x). This Information Disclosure Statement contains a listing of references which were cited in a Search Report issued by the International Searching Authority on February 3, 1999. A copy of the Search Report and the references are enclosed herewith.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accordance with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with Applicants' belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

The references listed on the PTO-FB-A820 are as follows:





U.S. Patents

3,471,503, issued October 7, 1969

Other Documents

P. Mazzocchi et al., "Synthesis and Pharmacological Activity of 2,3,4,5-Tetrahydro-1,5-methano-1H-3-benzazepines," J. Med. Chem., 22(4), 455-457 (1979).

Applicants also bring to the attention of the Examiner U.S. co-pending application Ser. No. 09/514,002, filed February 25, 2000, which is a continuation in part application of the present application.

A favorable response is earnestly solicited.

Respectfully submitted,

Date: 12/29/2000

Roy F. Waldron
Attorney for Applicant(s)
Reg. No. 42,208

Pfizer Inc
Patent Department, 20th Floor
235 East 42nd Street
New York, NY 10017-5755
(212) 733-5086